Resolution Bioscience Inks Liquid Biopsy Collaboration With Leidos Biomedical Research | GenomeWeb

NEW YORK (GenomeWeb) – Resolution Bioscience said today that it has made an agreement with Leidos Biomedical Research to evaluate Resolution's liquid biopsy technology.

Under the agreement, the Frederick National Laboratory for Cancer Research, which Leidos operates, will begin using Resolution's "ctDx" sequencing chemistries and bioinformatics pipeline as part of its evaluation of various liquid biopsy technologies.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.